Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
1.
Pediatr Nephrol ; 27(6): 933-9, 2012 Jun.
Article in English | MEDLINE | ID: mdl-22311342

ABSTRACT

BACKGROUND: Corticosteroids have been shown not to prevent the development of Henoch-Schönlein nephritis. However, long-term follow-up data are scarce. METHODS: The long-term outcome of patients in a randomized placebo-controlled prednisone study was evaluated 8 years later with a health questionnaire completed by 160/171 (94%) patients and by urine and blood pressure screening (138/171, 81%). RESULTS: Twelve patients had hematuria and/or proteinuria and seven had hypertension. The patients with nephritis at onset of Henoch-Schönlein purpura (HSP) had an increased risk of hypertension and/or urine abnormalities (odds ratio 3.6, p = 0.022, 95% confidence interval 1.3-10.0). There were no differences between the prednisone and placebo groups. Recurrences of purpura were reported by 15 patients, with some recurrences continuing for 10 years. All five reported pregnancies were complicated by proteinuria. Four patients presented with hematuria and/or proteinuria at the control visit, and four had hypertension. Of these, two had a decreased estimated glomerular filtration rate. CONCLUSIONS: HSP has a good long-term prognosis in unselected patients, although skin relapses with/without late-onset nephritis may occur, even a decade after the initial disease. Urine and blood pressure abnormalities 8 years after HSP are associated with nephritis at its onset. Early prednisone treatment does not affect the outcome and should not be routinely used.


Subject(s)
Glucocorticoids/therapeutic use , IgA Vasculitis/drug therapy , Prednisone/therapeutic use , Adolescent , Adult , Blood Pressure , Chi-Square Distribution , Child , Double-Blind Method , Female , Finland , Hematuria/etiology , Hematuria/urine , Humans , Hypertension/etiology , Hypertension/physiopathology , IgA Vasculitis/complications , Male , Nephritis/etiology , Nephritis/urine , Odds Ratio , Placebos , Proteinuria/etiology , Proteinuria/urine , Recurrence , Risk Assessment , Risk Factors , Surveys and Questionnaires , Time Factors , Treatment Outcome , Young Adult
2.
Pediatr Nephrol ; 26(12): 2159-66, 2011 Dec.
Article in English | MEDLINE | ID: mdl-21626222

ABSTRACT

Knowledge about how to treat severe Henoch-Schönlein nephritis (HSN) is scarce. The aim of our study is to compare cyclosporine A (CyA) and methylprednisolone pulses (MP) in the treatment of severe HSN. Out of 24 pediatric HSN patients with nephrotic-range proteinuria or crescentic HSN in kidney biopsy, seven were randomized to receive CyA for 12 months at an initial dose of 5 mg/kg and eight to receive 3 MP pulses of 30 mg/kg followed by prednisone for 4 months. The other nine patients received identical treatment without randomization. Kidney biopsies were performed at inclusion and after 2 years. The primary outcomes were the duration of proteinuria and hematuria, estimated glomerular filtration rate, and renal biopsy histology. All the 11 CyA-treated patients achieved resolution of nephrotic-range proteinuria within 3 months, while the MP-group response was slower, and in 6/13 was not achieved with the initial treatment. Additional immunosuppressive treatment was needed in none of the CyA-treated patients but in six patients treated with MP (difference in proportion 46%, p = 0.008). The 2-year control biopsies were similarly improved in both groups. After mean 6.1 years (2.2-10.4 years), 16 patients (eight CyA, eight MP) had no renal symptoms and six (three CyA, three MP) had persistent nephropathy but normal renal function. One MP-treated patient had reduced renal function and another had developed ESRD and received a renal transplant. CyA gave a 100% resolution of nephrotic-range proteinuria and a 100% renal survival rate without additional therapy after a mean follow-up of 6 years. Treatment of HSN with CyA is efficacious, safe and not inferior to MP.


Subject(s)
Cyclosporine/therapeutic use , IgA Vasculitis/drug therapy , Immunosuppressive Agents/therapeutic use , Methylprednisolone/therapeutic use , Nephritis/drug therapy , Adolescent , Child , Child, Preschool , Female , Humans , IgA Vasculitis/complications , Male , Nephritis/etiology
3.
Arch Dis Child ; 95(11): 877-82, 2010 Nov.
Article in English | MEDLINE | ID: mdl-20852275

ABSTRACT

OBJECTIVE: To assess the risk factors for developing Henoch-Schönlein purpura nephritis (HSN) and to determine the time period when renal involvement is unlikely after the initial disease onset. DESIGN: A prospective study of 223 paediatric patients to examine renal manifestations of Henoch-Schönlein purpura (HSP). The patient's condition was monitored with five outpatient visits to the research centre and urine dipstick testing at home. RESULTS: HSN occurred in 102/223 (46%) patients, consisting of isolated haematuria in 14%, isolated proteinuria in 9%, both haematuria and proteinuria in 56%, nephrotic-range proteinuria in 20% and nephrotic-nephritic syndrome in 1%. The patients who developed HSN were significantly older than those who did not (8.2±3.8 vs 6.2±3.0 years, p<0.001, CI for the difference 1.1 to 2.9). Nephritis occurred a mean of 14 days after HSP diagnosis, and within 1 month in the majority of cases. The risk of developing HSN after 2 months was 2%. Prednisone prophylaxis did not affect the timing of the appearance of nephritis. The risk factors for developing nephritis were age over 8 years at onset (OR 2.7, p=0.002, CI 1.4 to 5.1), abdominal pain (OR 2.1, p=0.017, CI 1.1 to 3.7) and recurrence of HSP disease (OR 3.1, p=0.002, CI 1.5 to 6.3). Patients with two or three risk factors developed nephritis in 63% and 87% of cases, respectively. Laboratory tests or blood pressure measurement at onset did not predict the occurrence of nephritis. CONCLUSION: The authors recommend weekly home urine dipstick analyses for the first 2 months for patients with HSP. Patients with nephritis should be followed up for more than 6 months as well as the patients with HSP recurrence.


Subject(s)
IgA Vasculitis/complications , Nephritis/etiology , Adolescent , Age Distribution , Age of Onset , Child , Child, Preschool , Epidemiologic Methods , Glucocorticoids/therapeutic use , Hematuria/etiology , Humans , Nephritis/diagnosis , Nephritis/prevention & control , Prednisone/therapeutic use , Prognosis , Proteinuria/etiology , Recurrence , Time Factors , Urinalysis/methods
4.
Arch Dis Child ; 95(11): 871-6, 2010 Nov.
Article in English | MEDLINE | ID: mdl-20371584

ABSTRACT

OBJECTIVE: To describe the extrarenal symptoms and clinical course of Henoch-Schönlein purpura (HSP). DESIGN: A prospective national multicentre trial with 6-month follow-up. Patients A total of 223 newly diagnosed paediatric HSP patients. RESULTS: Purpura was the initial symptom in 73% of the patients and was preceded by joint or gastrointestinal manifestations in the rest by a mean of 4 days. Joint symptoms, abdominal pain, melena, nephritis and recurrences occurred in 90%, 57%, 8%, 46% and 25% of the patients, respectively. Orchitis affected 17/122 (14%) of the boys. Seven patients developed protein-losing enteropathy characterised by abdominal pain, oedema and serum albumin under 30 g/l, and an additional 49 patients had subnormal albumin levels without any proteinuria. Positive fecal occult blood (26/117, 22%) and α1-antitrypsin (7/77, 9%) suggested mucosal injury even in the patients without gastrointestinal symptoms. HSP was often preceded by various bacterial, especially streptococcal (36%) and viral infections. Previous streptococcal infection did not induce changes in the level of complement component C3. Recurrences were more frequent in patients >8 years of age (OR 3.7, CI 2.0 to 7.0, p<0.001) and in patients with nephritis (OR 4.6, CI 2.3 to 8.9, p<0.001). Patients with severe HSP nephritis had more extrarenal symptoms up to 6 months. There was no difference in the clinical course between the prednisone-treated and non-treated patients during the 6-month follow-up. CONCLUSIONS: Serum albumin is often low in HSP patients without proteinuria, due to protein loss via the intestine. Although corticosteroids alleviate the symptoms, they seem not to alter the clinical course of HSP during 6 months of follow-up.


Subject(s)
Glucocorticoids/therapeutic use , IgA Vasculitis/drug therapy , Adolescent , Child , Child, Preschool , Cyclosporine/therapeutic use , Epidemiologic Methods , Female , Gastrointestinal Diseases/drug therapy , Gastrointestinal Diseases/etiology , Humans , IgA Vasculitis/complications , IgA Vasculitis/microbiology , Infant , Joint Diseases/drug therapy , Joint Diseases/etiology , Male , Methylprednisolone/therapeutic use , Orchitis/drug therapy , Orchitis/etiology , Prednisone/therapeutic use , Prognosis , Recurrence , Serum Albumin/metabolism , Streptococcal Infections/complications , Treatment Outcome , Virus Diseases/complications
5.
Kidney Int ; 74(8): 1085-93, 2008 Oct.
Article in English | MEDLINE | ID: mdl-18827800

ABSTRACT

Congenital chloride diarrhea is due to mutations in the intestinal Cl(-)/HCO(3)(-) exchange (SLC26A3) which results in sodium chloride and fluid depletion leading to hypochloremic and hypokalemic metabolic alkalosis. Although treatment with sodium and potassium chloride offers protection from renal involvement in childhood, the long-term renal outcome remains unclear. Here we describe two cases of congenital chloride diarrhea-associated end-stage renal disease with transplantation. Further, we show that there is a high incidence of mild chronic kidney disease in 35 other patients with congenital chloride diarrhea. The main feature of the renal injury was nephrocalcinosis, without hypercalciuria or nephrolithiasis with small sized kidneys and commensurately reduced glomerular filtration rates. This suggests that diarrhea-related sodium chloride and volume depletion, the first signs of non-optimal salt substitution, promote urine supersaturation and crystal precipitation. The poor compliance with salt substitution along with long-lasting hypochloremic and hypokalemic metabolic alkalosis is likely to induce progressive calcification and renal failure. Both our patients developed nephrocalcinosis in the transplanted kidneys suggesting that this complication is a consequence of intestinal SLC26A3 deficiency. Interestingly, the transporter is expressed in the distal nephron but the recurrence of nephrocalcinosis in the transplanted kidney suggests that it does not play a significant renal role in this syndrome.


Subject(s)
Diarrhea/congenital , Kidney Diseases/pathology , Sodium Chloride/adverse effects , Adolescent , Adult , Antiporters/genetics , Child, Preschool , Chloride-Bicarbonate Antiporters , Chronic Disease , Diarrhea/chemically induced , Diarrhea/genetics , Female , Humans , Kidney/pathology , Kidney Diseases/etiology , Kidney Transplantation , Longitudinal Studies , Male , Mutation , Nephrocalcinosis , Organ Size , Sulfate Transporters , Treatment Outcome , Young Adult
7.
J Pediatr ; 149(2): 241-7, 2006 Aug.
Article in English | MEDLINE | ID: mdl-16887443

ABSTRACT

OBJECTIVE: To evaluate the efficacy of early prednisone therapy in preventing renal and treating extrarenal and renal symptoms in Henoch-Schönlein purpura (HSP) in a placebo-controlled trial. STUDY DESIGN: A total of 171 patients (84 treated with prednisone and 87 receiving placebo) were included and followed up for 6 months. The endpoints were renal involvement at 1, 3, and 6 months and healing of extrarenal symptoms. The analyses were performed on an intent-to-treat basis. RESULTS: Prednisone (1 mg/kg/day for 2 weeks, with weaning over the subsequent 2 weeks) was effective in reducing the intensity of abdominal pain (pain score, 2.5 vs 4.8; P = .029) and joint pain (4.6 vs 7.3; P = .030). Prednisone did not prevent the development of renal symptoms but was effective in treating them; renal symptoms resolved in 61% of the prednisone patients after treatment, compared with 34% of the placebo patients (difference = 27%; 95% confidence interval = 3% to 47%; P = .024). CONCLUSIONS: The general use of prednisone in HSP is not supported, but patients with disturbing symptoms may benefit from early treatment, because prednisone reduces extrarenal symptoms and is effective in altering (but not preventing) the course of renal involvement.


Subject(s)
Anti-Inflammatory Agents/therapeutic use , IgA Vasculitis/drug therapy , Prednisone/therapeutic use , Abdominal Pain/diagnosis , Abdominal Pain/epidemiology , Adolescent , Anti-Inflammatory Agents/adverse effects , Arthralgia/diagnosis , Arthralgia/epidemiology , Child , Double-Blind Method , Drug Administration Schedule , Female , Humans , IgA Vasculitis/epidemiology , Kidney Diseases/diagnosis , Kidney Diseases/epidemiology , Male , Prednisone/adverse effects , Prevalence , Prospective Studies , Risk Factors , Severity of Illness Index , Treatment Outcome
8.
Pediatr Nephrol ; 21(9): 1266-73, 2006 Sep.
Article in English | MEDLINE | ID: mdl-16838184

ABSTRACT

We evaluated the natural long-term outcome after childhood IgA nephritis. Altogether 55 patients with biopsy-proven IgA nephritis were identified, 37 (67%) responded to the health questionnaire and 31 (56%) participated in the medical examination after a mean follow-up of 18.7 years (SD 6.2; range 8.5-29.8). The results of medical examination, onset data and the re-analysis of original biopsies of 31 participants were used when analyzing the predictive factors for persistent nephropathy, i.e. constant proteinuria/hematuria or end-stage renal disease (ESRD). All patients' medical history data were obtained from regional hospitals and renal survival data from the national kidney register. Six (11%) of the 55 identified patients had developed ESRD. Sixteen (52%) of the 31 participants were not attending for regular follow-up visits after the acute phase. Twenty-two (71%) had renal symptoms and 12 (39%) were receiving drugs for hypertension/proteinuria at their latest follow-up visit. The chronicity index and total biopsy score in the first renal biopsy were higher in patients with persistent nephropathy or ESRD than in those without (p=0.022 and p=0.014, respectively). Nine (69%) of the 13 subjects who had been over 16 years of age at diagnosis had persistent nephropathy or ESRD, compared with 4 (22%) of the 18 subjects who had been under 16 years of age (relative risk 3.1, 95% CI 1.2-8.0). Pregnancy complications were common: 12 (55%) of the 22 pregnancies had been complicated by proteinuria and/or hypertension, and the prematurity rate was 30%. Long-term follow-up during adulthood is needed even after mild childhood IgA nephritis, especially in women during and after pregnancy.


Subject(s)
Glomerulonephritis, IGA/physiopathology , Adolescent , Adult , Child , Cohort Studies , Female , Follow-Up Studies , Humans , Male , Pregnancy , Retrospective Studies
9.
J Pediatr Gastroenterol Nutr ; 42(4): 369-75, 2006 Apr.
Article in English | MEDLINE | ID: mdl-16641574

ABSTRACT

OBJECTIVES: Congenital chloride diarrhea (CLD) is a rare, autosomal recessive disorder of intestinal Cl/HCO3 exchange caused by mutations in the SLC26A3 gene and characterized by persistent Cl rich diarrhea from birth. Treatment is symptomatic and replacement therapy with NaCl and KCl has been shown to be effective in children, but the long-term prognosis remains unclear. We studied the largest known cohort of patients to evaluate the long-term outcome of CLD and to search for extraintestinal manifestations. METHODS: This is a cross-sectional clinical evaluation and retrospective analysis of medical history of 36 Finnish patients with CLD, born in the 1960s (n = 8), 1970s (n = 7) and 1980s (n = 21). RESULTS: Early diagnosis and aggressive salt replacement therapy were associated with normal growth and development, in addition to significantly reduced mortality rates among the groups of patients born in the different decades, respectively (P = 0.001). No deaths due to CLD were observed after 1972. Enuresis, slight soiling and hospitalizations for gastroenteritis were common, especially in childhood, but 92% of the patients found their health excellent or good. Complications documented were end-stage renal disease (n = 1) and hyperuricemia (n = 4), novel findings possibly associated with CLD being male subfertility (n = 3), spermatoceles (n = 3), intestinal inflammation (n = 2), inguinal hernias (n = 4) and increased concentrations of sweat Cl in 12% of the patients. CONCLUSIONS: When early diagnosed and adequately treated, the long-term prognosis of CLD is favorable. A putative role of a primary anion exchange defect of SLC26A3 in male subfertility and the decline of renal function due to chronic dehydration deserve further characterization.


Subject(s)
Chlorides/metabolism , Chlorides/therapeutic use , Diarrhea/genetics , Diarrhea/therapy , Adolescent , Adult , Antiporters , Child , Child, Preschool , Chloride-Bicarbonate Antiporters , Cross-Sectional Studies , Diarrhea/congenital , Female , Humans , Infant , Infant, Newborn , Male , Mutation , Prognosis , Quality of Life , Retrospective Studies , Sulfate Transporters , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...